Main aspects of oral and maxillofacial surgery in the patient under bisphosphonate therapy
DOI:
https://doi.org/10.33448/rsd-v11i15.37839Keywords:
Osteonecrosis; Osteogenesis; Oral surgery.Abstract
Bisphosphonates are a class of compounds used to treat many different medical conditions. Its use has increased dramatically in recent years as new indications for its use have emerged. Current indications include the treatment of multiple myeloma, hypercalcemia, osteolytic lesions of metastatic disease, Paget's disease, and, most commonly, osteoporosis. While these drugs are beneficial, a significant and potentially devastating complication - osteonecrosis of the jaws - has been reported termed bisphosphonate-related osteonecrosis (BRON), and has been increasingly recognized. In this context, this study aims to carry out a literature review regarding the main aspects of oral and maxillofacial surgery in patients undergoing therapy with bisphosphonates, and to report the clinical manifestations of mandibular osteonecrosis related to the drug in question. In order to achieve this objective, a bibliographical survey was carried out in the databases SciVerse Scopus, Scientific Electronic Library Online (Scielo), U.S. National Library of Medicine (PUBMED) and ScienceDirect. The results indicate that, with the increasing use of bisphosphonates in the female population, BRON of the mandible is likely to be an increasing problem that will require complex treatment and management by oral and maxillofacial surgeons. As such, our expertise will be critical in providing answers to difficult questions of management and treatment outcomes. Unfortunately, at this time, only palliative care can be offered to patients suffering from this potentially devastating process. Increased awareness and vigilance can reduce potential complications. More studies looking at specific risk factors may help prevent this process before it starts.
References
De Almeida Freire, N., Heimlich, F. V., Ramos, M. E. B., Antero, S. A. F., & Israel, M. S. (2020). “Prevention protocol for bisphosphonate-related osteonecrosis of the jaws in a patient with HIV.” Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology 129(1):e131–32. doi: https://doi.org/10.1016/j.oooo.2019.06.575.
Alzoman, H. A. (2011). “Prevalence of Jaw Osteonecrosis among Patients Receiving Bisphosphonates in Riyadh.” King Saud University Journal of Dental Sciences 2(1):29–32. https://doi.org/10.1016/j.ksujds.2011.03.001.
Bernardinho, Í. M., Leal, T. R., Filho, R. A. M., Dias, G., & Gomes. (2009). Osteonecrose dos maxilares associada à utilização de bisfosfonatos: quais as evidências científicas atuais? Vol. 3322.
Colella, G., Campisi, G., & Fusco,V. (2009). “American Association of Oral and Maxillofacial Surgeons Position Paper: Bisphosphonate-Related Osteonecrosis of the Jaws—2009 Update: The Need to Refine the BRONJ Definition.” Journal of Oral and Maxillofacial Surgery 67(12):2698–99. doi: https://doi.org/10.1016/j.joms.2009.07.097.
Graves, L. L., Bukata, S. V., Nona Aghazadehsanai, T. I., Chang, N. R. G., & Friedlander, A. H. (2016). “Patients Receiving Parenteral Bisphosphonates for Malignant Disease and Having Developed an Atypical Femoral Fracture Are at Risk of Concomitant Osteonecrosis of the Jaw: An Evidence-Based Review.” Journal of Oral and Maxillofacial Surgery 74(12):2403–8. https://doi.org/10.1016/j.joms.2016.06.003.
Heufelder, M. J., Hendricks, J., Remmerbach, T., Frerich, B., Hemprich, A., & Wilde, F. (2014). “Principles of Oral Surgery for Prevention of Bisphosphonate-Related Osteonecrosis of the Jaw.” Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology 117(6):e429–35. doi: https://doi.org/10.1016/j.oooo.2012.08.442.
Loureiro, C. C. S., & Leandro, L. F. L. (2010). “Advantages and Disadvantages of the Use of Bisphosphonates in Oral and Maxillofacial Surgery.” International Dental Journal 60(4):263–68. https://doi.org/10.1922/IDJ_2519Pierotti06.
McLeod, N. M. H., Brennan, P. A., & Ruggiero, S. L. (2012). “Bisphosphonate Osteonecrosis of the Jaw: A Historical and Contemporary Review.” The Surgeon 10(1):36–42. doi: https://doi.org/10.1016/j.surge.2011.09.002.
Menga, E. N., Webb, A. J., & Mesfin, A. (2018). “Do Bisphosphonates Affect Fusion Rates? How to Manage These Medications in the Perioperative Time Frame.” Seminars in Spine Surgery 30(1):46–48. https://doi.org/10.1053/j.semss.2017.09.009.
Nadar, R. A., G. M., Franssen, N. W. M., Van Dijk, K,. Codee-van der Schilden, M., de Weijert, E., Oosterwijk, M., Iafisco, N., Margiotta, S., Heskamp, J. J. J. P., van den Beucken, & Leeuwenburgh, S. C. G. (2021). “Bone Tumor–Targeted Delivery of Theranostic 195mPt-Bisphosphonate Complexes Promotes Killing of Metastatic Tumor Cells.” Materials Today Bio 9:100088. https://doi.org/10.1016/j.mtbio.2020.100088.
Nisi, M., F. La Ferla, D. Karapetsa, S. Gennai, M. Miccoli, A. Baggiani, F. Graziani, & M. Gabriele. 2015. “Risk Factors Influencing BRONJ Staging in Patients Receiving Intravenous Bisphosphonates: A Multivariate Analysis.” International Journal of Oral and Maxillofacial Surgery 44(5):586–91. doi: https://doi.org/10.1016/j.ijom.2015.01.014.
Olson, K. B., C. Michael Hellie, & Pienta, K. J. 2005. “Osteonecrosis of Jaw in Patient with Hormone-Refractory Prostate Cancer Treated with Zoledronic Acid.” Urology 66(3):658.e1-658.e3. https://doi.org/10.1016/j.urology.2005.03.028.
Patntirapong, Somying, Pawinee Phupunporn, Daranee Vanichtantiphong, and Watcharawee Thanetchaloempong. 2019. “Inhibition of Macrophage Viability by Bound and Free Bisphosphonates.” Acta Histochemica 121(4):400–406. https://doi.org/10.1016/j.acthis.2019.02.007.
Pereira, A., Shitsuka, D., Parreira, F., and Shitsuka, R. 2018. Método Qualitativo, Quantitativo Ou Quali-Quanti.
Rogers, M. J., D. Ph, S. Gordon, D. Ph, H. L. Benford, B. Sc, S. P. Luckman, & D. Ph. 2015. “Bisphosphonates.”
Santini, D., U. Vespasiani Gentilucci, B., Vincenzi, A., Vasaturo, P., F., La Cesa, A., Onori, N., Scarpa, S., & Tonini, G. 2003. “The Antineoplastic Role of Bisphosphonates: From Basic Research to Clinical Evidence.” Annals of Oncology 14(10):1468–76. doi: https://doi.org/10.1093/annonc/mdg401.
Vuorimies, I., Heidi Arponen, Helena Valta, Outi Tiesalo, Marja Ekholm, Helena Ranta, Marjut Evälahti, Outi Mäkitie, and Janna Waltimo-Sirén. 2017. “Timing of Dental Development in Osteogenesis Imperfecta Patients with and without Bisphosphonate Treatment.” Bone 94:29–33. https://doi.org/10.1016/j.bone.2016.10.004.
Yamashita, J., Sawa, N., Sawa, Y., & Miyazono, S. 2021. “Effect of Bisphosphonates on Healing of Tooth Extraction Wounds in Infectious Osteomyelitis of the Jaw.” Bone 143:115611. https://doi.org/10.1016/j.bone.2020.115611.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Rafael Meneses Bomfim; Wanessa Maurício da Silva; Kimberly Damazio Tiburcio; Jamesson dos Santos Celestino; Ana Letícia de Albuquerque Oliveira ; Yanca dos Santos; Talita Gomes Diniz; Rhuan Alexandre Pereira da Silva; Ana Lúcia de Matos Paz; Davi Torquato Dantas
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
